Foundation Fighting Blindness announced that genetic medicines for six types of LCA are being evaluated in clinical trials.
Public source
Publisher name
Public post
Spotlight on Leber congenital amaurosis (LCA) 👁️🗨️ Research is changing what's possible for people with LCA. LUXTURNA®, the first FDA-approved gene therapy for an inh…
Company
Foundation Fighting Blindness
We are driving research finding treatments and cures for blinding retinal diseases.
- Industry
- Research Services
- Location
- Columbia, US
- Company size
- 51–200 employees
About Foundation Fighting Blindness
The urgent mission of the Foundation Fighting Blindness is to drive the research that will provide preventions, treatments and cures for people affected by retinitis pigmentosa, Usher syndrome, Stargardt disease, Leber congenital amaurosis, age-related macular degeneration, and the spectrum of retinal degenerative diseases.
See moreLatest activity
Latest activity from Foundation Fighting Blindness
13 signals
Research & Knowledge
Foundation Fighting Blindness is currently accepting applications for its Individual Investigator Research Award, Postdoctoral Fellowship Award, and Clinical Research Fellowship Award.
Partnerships
Foundation Fighting Blindness supports funding opportunities for research across inherited retinal diseases and dry age-related macular degeneration.
Presence & Recognition
Foundation Fighting Blindness is hosting National VisionWalk Day on October 31, 2026, featuring a live-streamed program, challenges, community milestones, and a virtual ribbon cutting ceremony.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
The Smith-Kettlewell Eye Research Institute
The Smith-Kettlewell Eye Research Institute published research exploring binocular rivalry dynamics as a potential diagnostic marker for amblyopia.
Research & Knowledge
Cleveland Sight Center
Cleveland Sight Center is conducting a trial to see if cellular-rejuvenation therapy will reverse age-related diseases like glaucoma after 30 years of research and hard work.
Research & Knowledge
Opus Genetics
Opus Genetics will present topline clinical data from Cohort 1 of its Phase 1/2 study of OPGx-BEST1 gene therapy for patients with BEST1-related inherited retinal diseases.
Research & Knowledge
BrightFocus Foundation
BrightFocus Foundation's Dr. Karl Wahlin is working on rebuilding damaged retinal tissue through cell replacement in a research grantee role.
Research & Knowledge
Friedreich's Ataxia Research Alliance (FARA)